Clinical Trials Logo

Pancreas Cancer clinical trials

View clinical trials related to Pancreas Cancer.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT05702385 Withdrawn - Pancreas Cancer Clinical Trials

Clinical Utility Study for Exo-PDAC

Start date: September 1, 2023
Phase: N/A
Study type: Interventional

This is a national-level research study of oncologists, interventional gastroenterologists, and primary care providers. The purpose of this study is to assess the clinical evaluation and management (drug, procedures, counseling and other) of a subset of common patient care indications.

NCT ID: NCT05471401 Withdrawn - Lung Cancer Clinical Trials

GI Organ Tracking Via Balloon Applicators

Start date: April 25, 2023
Phase: N/A
Study type: Interventional

The hypothesis of this study is that an occlusion balloon catheter placed in the stomach via an oral or nasogastric route will be safe and permit tracking of the stomach during radiation therapy.

NCT ID: NCT05216120 Withdrawn - Pancreas Cancer Clinical Trials

Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas

Start date: June 14, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this research is to determine the benefit of pemigatinib in patients with advanced metastatic or surgically unresectable adenosquamous carcinoma of the pancreas who have progressed on previous therapy.

NCT ID: NCT05181865 Withdrawn - Gastric Cancer Clinical Trials

Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors

Start date: January 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2a, first-in-human, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of FL-301 in patients with advanced cancer.

NCT ID: NCT04833959 Withdrawn - Pancreas Cancer Clinical Trials

Pilot Study of 89-Zr Panitumumab in Pancreas Cancer

Start date: March 26, 2021
Phase: Phase 1
Study type: Interventional

The main purpose of the study is to assess the safety of 89Zr-panitumumab as a molecular imaging agent in patients with (metastatic) pancreas cancer.

NCT ID: NCT04584775 Withdrawn - Breast Cancer Clinical Trials

Implementing Acupuncture and Chinese Herbal Medicine Into Palliative Care

Start date: February 2021
Phase: N/A
Study type: Interventional

In this clinical trial we want to investigate the clinical benefit of a complementary therapy using therapeutical modalities of the traditional chinese medicine in patients suffering from advanced cancer.

NCT ID: NCT04123574 Withdrawn - Pancreatic Cancer Clinical Trials

A Pilot Study of BXCL701 in Patients With Pancreatic Cancer

Start date: October 15, 2019
Phase: Early Phase 1
Study type: Interventional

A study to assess the biochemical and immunomodulatory effects of BXCL701 in pancreatic cancer.

NCT ID: NCT03908333 Withdrawn - Pancreatic Cancer Clinical Trials

High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Start date: May 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to see if a combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin when given with high dose Ascorbic Acid will be safe and effective in individuals with untreated metastatic pancreatic cancer. Vitamin C is a nutrient found in food and dietary supplements. It protects cells and also plays a key role in making collagen (which provides strength and structure to skin, bones, tissues and tendons). High-dose vitamin C may be given by intravenous (IV) infusion (through a vein into the bloodstream) or orally (taken by mouth). When taken by intravenous infusion, vitamin C can reach much higher levels in the blood than when the same amount is taken by mouth. Some human studies of high-dose IV vitamin C in patients with cancer have shown improved quality of life, as well as improvements in physical, mental, and emotional functions, symptoms of fatigue, nausea and vomiting, pain, and appetite loss. Intravenous high-dose ascorbic acid has caused very few side effects in clinical trials.

NCT ID: NCT03778879 Withdrawn - Pancreas Cancer Clinical Trials

Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B

Start date: August 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Standard treatment for newly diagnosed operable pancreatic cancer usually involves undergoing surgery first and then receiving chemotherapy with or without radiation therapy. However, the pancreatic cancer often comes back after this treatment. Therefore, the investigators are studying whether giving treatment prior to surgery can help decrease the risk the cancer returns. Stereotactic Body Radiation Therapy (SBRT) is a highly focused type of radiation therapy commonly used in the treatment of pancreatic cancer. This treatment has been shown to be safe and effective for the preoperative treatment of pancreatic cancer. The purpose of this study is to determine if combining an experimental drug, CCX872-B, with SBRT continues to be safe and whether the combination treatment may be more effective at boosting the participant's immune system's ability to kill the pancreatic cancer.

NCT ID: NCT03760614 Withdrawn - Pancreas Cancer Clinical Trials

A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma

Start date: January 2021
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to find the best dose of entinostat when given in combination with FOLFOX for pancreatic cancer.